Trial Search Results
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Jasper Therapeutics, Inc.
Stanford Investigator(s):
Intervention(s):
- Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Phase:
Phase 1
Eligibility
Key Inclusion Criteria:
- AML/MDS as defined by specific criteria, including but not limited to the following
subtypes:
1. AML in CR
2. MDS < 5% BM blasts
3. MDS 5 - 10% BM blasts
4. AML not in CR or MDS > 10% BM blasts
- Patients with human leukocyte antigen (HLA) matched related or unrelated donors
- Adequate end organ function as defined in study protocol
Key Exclusion Criteria:
- Patients with any acute or uncontrolled infections
- Patients receiving any other investigational agents
- Patients with active non-hematologic malignancy
- Prior allogeneic hematologic cell transplantation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michelle Chin
650-721-4183
Recruiting